Collectively, the results of this study provide sufficient evidence that miR‐125a is a potential therapeutic target for CRC and that the miR‐125a/Smurf1 pathway may contribute to the development of new therapeutic strategies for CRC. This evidence concerns the gene SMURF1 and colorectal carcinoma.